Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of Bursa stocks as of Dec 19th. The aggregated short interest is USD461m.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Guan Chong, VS Industry, Datasonic, Genting Malaysia, Yinson.</li>
</ul>


We analyzed the changes in short interest of Bursa stocks as of Dec 19th. The aggregated short interest is USD461m.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Guan Chong, VS Industry, Datasonic, Genting Malaysia, Yinson.


Bursa Short Interest Weekly (Dec 19th): Guan Chong, VS Industry, Datasonic, Genting Malaysia, Yinson

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Fosun Pharma is acquiring 53% stake in Green Valley Pharmaceuticals for ~$200M, to bolster CNS portfolio. Hansoh Pharmaceutical entered an exclusive license agreement with Glenmark Pharma for NSCLC drug Ameile.</li>
<li>Daiichi Sankyo received FDA approval for Enhertu as first-line treatment for HER2+ breast cancer. Takeda Pharmaceutical announced positive topline results for two P3 studies of zasocitinib in moderate-to-severe plaque psoriasis.</li>
<li>Hanmi Pharmaceutical filed domestic marketing application for efpeglenatide autoinjector, the first domestically developed GLP-1-based obesity drug. Max Healthcare announced INR10B+ investment for a ~450 bedded hospital in Pune.</li>
</ul>


Fosun Pharma is acquiring 53% stake in Green Valley Pharmaceuticals for ~$200M, to bolster CNS portfolio. Hansoh Pharmaceutical entered an exclusive license agreement with Glenmark Pharma for NSCLC drug Ameile.
Daiichi Sankyo received FDA approval for Enhertu as first-line treatment for HER2+ breast cancer. Takeda Pharmaceutical announced positive topline results for two P3 studies of zasocitinib in moderate-to-severe plaque psoriasis.
Hanmi Pharmaceutical filed domestic marketing application for efpeglenatide autoinjector, the first domestically developed GLP-1-based obesity drug. Max Healthcare announced INR10B+ investment for a ~450 bedded hospital in Pune.


APAC Healthcare Weekly (December 21)–Fosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health

Vriddhi Consulting

Punit Khanna

Independent Insight Provider

Equity Bottom-Up

Poh Huat Resources Holdings / Equity Bottom-Up

Poh Huat Resources Holdings Berhad is an investment holding company.  The Company, through its subsidiaries, manufactures and trades furniture and parts.

<ul>
<li>Operations did not make any money. other income led to profits.</li>
<li>Cash per share is MYR 1.11 and the company trades below Cash.</li>
<li>The company is cautious on outlook due to increasing cost, weak demand , supply chain issue and tariffs.</li>
</ul>
 <div class="content-highlight">
 <h2>Raising Money for Persons with Disabilities in Singapore</h2>
 For your kind consideration
 This report has been prepared by Vriddhi Consulting, founded by Punit and Debjani Khanna. A portion of the research was contributed by Shubham Khanna, an individual on the autism spectrum.  We are grateful to Smartkarma for providing a platform to share this research and amplify its impact.
 All proceeds from the publication of this report will be donated to support people with disabilities in Singapore. If you find this report valuable, we invite you to support our campaign, “Raising Money for Persons with Disabilities in Singapore.” Every contribution directly benefits the Goh Chok Tong Enable Fund and qualifies for a 250% tax deduction for Singapore tax residents.
 To contribute, <a href="https://www.giving.sg/donate/campaign/raising-money-for-person-with-disabilities-empowering-visions-shaping-future" target="_blank" rel="noopener">please visit this URL.</a> 
 </div>


Operations did not make any money. other income led to profits.
Cash per share is MYR 1.11 and the company trades below Cash.
The company is cautious on outlook due to increasing cost, weak demand , supply chain issue and tariffs.

    
    Raising Money for Persons with Disabilities in Singapore
    For your kind consideration
    This report has been prepared by Vriddhi Consulting, founded by Punit and Debjani Khanna. A portion of the research was contributed by Shubham Khanna, an individual on the autism spectrum.  We are grateful to Smartkarma for providing a platform to share this research and amplify its impact.
    All proceeds from the publication of this report will be donated to support people with disabilities in Singapore. If you find this report valuable, we invite you to support our campaign, “Raising Money for Persons with Disabilities in Singapore.” Every contribution directly benefits the Goh Chok Tong Enable Fund and qualifies for a 250% tax deduction for Singapore tax residents.
    To contribute, please visit this URL. 
    
    

Poh Huat Full Year Results:  Deep Value Situation

Asian Economist

Kok Peng Chan

Macroeconomics

<ul>
<li>China’s low consumption ratio is driven by structural constraints—stagnant labour income, early and rapid household leverage, heavy debt burdens, declining workforce and persistent precautionary saving</li>
<li>Such constraints on household consumption mean recent policy announcements to expand overall domestic demand will take longer than expected to deliver a durable consumption-driven Chinese economy</li>
<li>China’s ten-year bond yield appears to recognise this reality, pricing in persistently weak nominal growth and subdued domestic demand rather than a consumption-driven reacceleration. It is now lower than Japan</li>
</ul>


China’s low consumption ratio is driven by structural constraints—stagnant labour income, early and rapid household leverage, heavy debt burdens, declining workforce and persistent precautionary saving
Such constraints on household consumption mean recent policy announcements to expand overall domestic demand will take longer than expected to deliver a durable consumption-driven Chinese economy
China’s ten-year bond yield appears to recognise this reality, pricing in persistently weak nominal growth and subdued domestic demand rather than a consumption-driven reacceleration. It is now lower than Japan


China’s Consumption Push: Will It Take Off?

Chief Economist, Aletheia Capital

Dr. Jim Walker

Chief Economist

Independent and original Asian investment research

Aletheia Capital

Aletheia Capital (HK) Ltd. (previously known as Asianomics) combines the extensive knowledge of its experienced team with technology and regulatory changes to disrupt Global Markets business in Asia. The firm is completely independent with no conflicts of interest either on Investment Banking advisory or Capital Markets execution.

<ul><li data-start="0" data-end="190">South Korean export prices rose 7 percent year on year, signaling a strong recovery after summer weakness, while Chinese real retail sales grew around 3 percent despite nominal softness.</li><li data-start="192" data-end="358">Chinese monetary aggregates expanded, with M2 up 8 percent and M0 growth at 10.6 percent, indicating monetary and credit support despite consumer price deflation.</li><li data-start="360" data-end="571" data-is-last-node="">Thailand cut interest rates slightly, Japanese yields surged beyond policy adjustments, and U.S. artificial intelligence investment faces structural limits, likely causing widespread disappointment in returns.</li></ul>

South Korean export prices rose 7 percent year on year, signaling a strong recovery after summer weakness, while Chinese real retail sales grew around 3 percent despite nominal softness.Chinese monetary aggregates expanded, with M2 up 8 percent and M0 growth at 10.6 percent, indicating monetary and credit support despite consumer price deflation.Thailand cut interest rates slightly, Japanese yields surged beyond policy adjustments, and U.S. artificial intelligence investment faces structural limits, likely causing widespread disappointment in returns.

Walker’s Weekly: Dr. Jim's Summary of Key Global Macro Developments -19 Dec 2025

Malaysia
Insights on Malaysia

Bursa Short Interest Weekly (Dec 19th): Guan Chong, VS Industry, Datasonic, Genting Malaysia, Yinson

We analyzed Bursa Malaysia short interest report for the past week and highlighted short interest changes in Guan Chong, VS Industry, Datasonic,...

Ke Yan, CFA, FRM

APAC Healthcare Weekly (December 21)–Fosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health

Fosun Pharma is acquiring 53% stake in Green Valley. Hansoh inked exclusive license agreement with Glenmark Pharma. Daiichi Sankyo’s Enhertu got...

Tina Banerjee

Poh Huat Full Year Results: Deep Value Situation

Company's operations are not profitable as demand is facing headwinds, but it has cash rich Balance Sheet which will support the company in downturn.

Punit Khanna

China’s Consumption Push: Will It Take Off?

This report shows why China’s consumption push faces structural limits, why rate cuts won’t work, and how delayed reform raises risks for equities,...

Kok Peng Chan

Walker’s Weekly: Dr. Jim's Summary of Key Global Macro Developments -19 Dec 2025

South Korean export prices rose 7 percent year on year, signaling a strong recovery after summer weakness, while Chinese real retail sales grew...

Dr. Jim Walker

Bursa Short Interest Weekly (Dec 19th): Guan Chong, VS Industry, Datasonic, Genting Malaysia, Yinson

We analyzed Bursa Malaysia short interest report for the past week and highlighted short interest changes in Guan Chong, VS Industry, Datasonic,...

Ke Yan, CFA, FRM

APAC Healthcare Weekly (December 21)–Fosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health

Fosun Pharma is acquiring 53% stake in Green Valley. Hansoh inked exclusive license agreement with Glenmark Pharma. Daiichi Sankyo’s Enhertu got...

Tina Banerjee

Poh Huat Full Year Results: Deep Value Situation

​Company's operations are not profitable as demand is facing headwinds, but it has cash rich Balance Sheet which will support the company in downturn.

Punit Khanna

China’s Consumption Push: Will It Take Off?

This report shows why China’s consumption push faces structural limits, why rate cuts won’t work, and how delayed reform raises risks for equities,...

Kok Peng Chan

Walker’s Weekly: Dr. Jim's Summary of Key Global Macro Developments -19 Dec 2025

South Korean export prices rose 7 percent year on year, signaling a strong recovery after summer weakness, while Chinese real retail sales grew...

Dr. Jim Walker

Company's operations are not profitable as demand is facing headwinds, but it has cash rich Balance Sheet which will support the company in downturn.